10-K: NexGel, Inc. Reports Significant Revenue Growth in 2024 Driven by Consumer Product Acquisitions

NexGel, Inc. announces a substantial 112.5% increase in revenue for 2024, primarily driven by growth in branded consumer products and strategic acquisitions.

Summary

• NexGel, Inc. reported a net revenue of $8.688 million for the year ended December 31, 2024, representing a 112.5% increase compared to $4.089 million in 2023.
• The revenue growth was primarily attributed to the expansion of branded consumer products, including $2.889 million from the Silly George acquisition.
• Gross profit increased to $2.748 million in 2024 from $374 thousand in 2023, with gross profit margin improving to 31.6% from 9.1%.
• Selling, general, and administrative expenses rose by 66.1% to $6.224 million, driven by increased advertising, marketing, and Amazon fees, as well as higher compensation and benefits.
• The company incurred a net loss of $3.463 million, compared to a net loss of $3.188 million in the previous year.
• Research and development expenses decreased slightly to $78 thousand in 2024 from $103 thousand in 2023.
• The company's cash and cash equivalents decreased to $1.807 million as of December 31, 2024, from $2.700 million at the end of 2023.
• NexGel completed the acquisition of Silly George in May 2024 and Kenkoderm in December 2023, expanding its consumer product portfolio.
• The company is focusing on expanding its sales channels in consumer products and developing a sales pipeline for potential customers.
• Management acknowledges the need for additional capital raises to fund potential acquisitions and achieve strategic objectives.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's significant revenue growth and strategic acquisitions, the company continues to incur net losses and faces challenges in achieving profitability. The identified material weaknesses in internal control over financial reporting also raise concerns.

Positives

• Significant revenue growth of 112.5% indicates strong market traction and successful expansion efforts.
• Improved gross profit margin suggests better cost management and pricing strategies.
• Strategic acquisitions of Silly George and Kenkoderm diversify the product portfolio and expand market reach.
• The rights offering in November 2024 provided $3.772 million in additional working capital.
• The company is actively exploring new product channels and developing a sales pipeline to enhance financial stability.

Negatives

• The company continues to incur net losses, indicating ongoing challenges in achieving profitability.
• Increased selling, general, and administrative expenses may impact overall financial performance.
• The company's cash reserves decreased, highlighting the need for effective cash management and potential future capital raises.
• Material weaknesses in internal control over financial reporting raise concerns about the reliability of financial information.
• The company's ability to continue as a going concern is dependent on managing and growing current products and achieving profitable operations.

Risks

• The company's future success depends on market acceptance of its existing and future products.
• Suppliers may fail to deliver components and raw materials, leading to production delays.
• The company relies heavily on Amazon and Shopify marketplaces, and disruptions could harm the business.
• The absence of contracts with customers could result in periods without revenues.
• The company operates in a highly competitive industry, facing competition from larger, more established players.
• Failure to protect intellectual property could negatively affect the company's ability to compete.
• The company has limited sales, marketing, and distribution capabilities.
• The company is reliant on two manufacturers for key ingredients used to manufacture of its hydrogels.
• The company has a history of operating losses and may require but have difficulty or be unsuccessful in raising potentially needed capital in the future to continue to operate as a going concern.
• The company's ability to provide customers with competitive services is dependent on its ability to attract and retain qualified personnel, including its senior management team.
• Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could significantly affect the company's financial results or financial condition.
• The company's ability to pursue strategic partnerships may impact its ability to compete in the markets it serves or desires to enter.
• Achieving the company's growth objectives may prove unsuccessful.
• An active trading market may not develop or be sustained, and the company's stock price may fluctuate significantly once it does trade.
• The company's failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of its common stock and warrants.
• The company cannot assure you that it will pay dividends on its common stock, and its indebtedness may limit its ability to pay dividends on its common stock.
• The interests of the company's principal stockholders, officers and directors, who collectively beneficially own approximately 16.3% of its stock, may not coincide with yours and such stockholders will have the ability to control decisions with which you may disagree.
• The company has identified material weaknesses in connection with its internal control over financial reporting which, if not remediated, could adversely affect its business, reputation and stock price.
• If securities or industry analysts do not publish research about the company's business, or publish negative reports about its business, its share price and trading volume could decline.
• Future sales or potential sales of the company's common stock in the public market could cause its share price to decline.
• The company may issue additional securities in the future upon conversion or exercise of outstanding securities which would result in dilution to its stockholders.
• The company is an emerging growth company and a smaller reporting company and may elect to comply with reduced public company reporting requirements applicable to emerging growth companies, and are subject to lesser public company reporting requirements applicable to smaller reporting companies, which could make its common stock less attractive to investors.
• The company will incur costs as a result of operating as a public company, and its management will be required to devote substantial time to new compliance initiatives.
• Provisions in the company's Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and of Delaware law may prevent or delay an acquisition of its company, which could decrease the trading price of its common stock.
• The company's Amended and Restated Bylaws include a forum selection clause, which could limit its stockholders ability to obtain a favorable judicial forum for disputes with it.

Future Outlook

Management is exploring new product channel sales in consumer products and developing a sales pipeline for potential customers. The company plans to continue building its catalogue of consumer products and develop its own proprietary medical devices. Additional capital raises through debt or equity may be necessary to achieve these objectives. The company expects to continue incurring losses for the near-term future.

Industry Context

NexGel operates in the hydrogel manufacturing industry, serving the wound care, medical diagnostics, transdermal drug delivery, and cosmetics markets. The company faces competition from larger, more established players in the consumer product and medical device sectors. Strategic partnerships are critical for success in the medical device business, while direct-to-consumer marketing is more feasible for consumer branded products.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• Without specific financial benchmarks for comparable companies in the hydrogel manufacturing, consumer product, and medical device industries, it's difficult to assess NexGel's performance against industry norms.
• Companies like Johnson & Johnson, Pfizer Consumer Healthcare, and Procter & Gamble are mentioned as competitors, but no specific financial comparisons are made.
• A more detailed analysis would require comparing NexGel's revenue growth, gross profit margins, and operating expenses to those of its direct competitors and industry averages.

Corporate Governance

Related Party Transactions

• As of December 31, 2024, the company had outstanding balances of $494 thousand due to C.G. Laboratories, Inc., a related party, for contract manufacturing, packaging, and other services.
• As of December 31, 2024, the company had an outstanding balance of $37 thousand due to Russell Crum, the CEO of CG Labs.
• Dr. Jerome Zeldis, a member of the company's board of directors, had an outstanding balance due of $25 thousand for services as of December 31, 2023, which was repaid in August 2024.

Stakeholder Impact

• Shareholders: The revenue growth and strategic acquisitions are positive, but the continued net losses and material weaknesses in internal control over financial reporting may raise concerns.
• Employees: The company's expansion efforts may create new opportunities, but the financial challenges could impact job security and compensation.
• Customers: The expanded product portfolio and focus on innovation may lead to better products and services.
• Suppliers: The company's growth could increase demand for raw materials and components.
• Creditors: The company's financial challenges may increase credit risk, but the recent capital raise provides some cushion.

Next Steps

• Management is exploring new product channel sales in consumer products.
• The company plans to continue building its catalogue of consumer products for sale to branding partners.
• The company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology.
• The company continues to evaluate strategic initiatives (e.g., acquisitions).
• The company intends to remediate the material weaknesses in internal control over financial reporting.

Key Dates

Keywords

revenue growth, consumer products, acquisitions, financial results, hydrogels, NexGel, Silly George, Kenkoderm, manufacturing, financials